Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01325701 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase 2 study of Diffuse Large Cell B-lymphoma, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 15
- Study locations
NCT01325701 is a Phase 2 study of Diffuse Large Cell B-lymphoma that has completed, run by Pharmacyclics. The registered enrollment target is 78 participants. The trial reports 15 study locations across 10 states.
The verdict
NCT01325701, a Phase 2 study of Diffuse Large Cell B-lymphoma, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of ibrutinib (PCI-32765) in relapsed/refractory de novo activated B-cell (ABC) and germinal-cell B-Cell (GCB) Diffuse Large B-cell Lymphoma (DLBCL).
Conditions Studied
Interventions
- DRUG ibrutinib
Study Locations (15)
New York
- Long Island Jewish Medical Center - New Hyde Park
- New York University - New York
- Weill Medical College of Cornell University - New York
- Memorial Sloan-Kettering Cancer Center - New York
- University of Rochester School of Medicine and Dentistry - Rochester
California
- UCLA Medical Center - Los Angeles
- Stanford University School of Medicine - Stanford
Maryland
- National Cancer Institute - Bethesda
Minnesota
- Mayo Clinic - Rochester
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- The Ohio Sate university - Columbus
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01325701
The ClinicalTrials.gov registry entry for NCT01325701 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Large Cell B-lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ibrutinib is the first listed.
NCT01325701 reports 15 study locations spanning 10 distinct geographic areas - top geographies include New York, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT01325701 about?
NCT01325701 is a clinical study titled "Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma". The purpose of this study is to evaluate the efficacy of ibrutinib (PCI-32765) in relapsed/refractory de novo activated B-cell (ABC) and germinal-cell B-Cell (GCB) Diffuse Large B-cell Lymphoma (DLBCL).
What is the current status of trial NCT01325701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2011-05. Estimated completion is 2014-10.
What conditions does trial NCT01325701 study?
This clinical trial studies the following conditions: Diffuse Large Cell B-lymphoma.
What interventions are being tested in trial NCT01325701?
The interventions under investigation include: ibrutinib (DRUG).
Who is sponsoring clinical trial NCT01325701?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01325701 being conducted?
This trial has 15 study locations across California, Maryland, Minnesota, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.